Novartis paid Takeda $3.4 billion for its FDA-approved dry eye drug Xiidra during the Japanese ... FDA approval of a phase 3 trial for eye drops containing tivanisiran, in dry eye disease associat ...
Shire’s CEO Flemming Ornskov has hailed the launch of ophthalmology drug Xiidra ... call about Xiidra, a blockbuster hopeful that Shire stuck with despite a rejection in dry eye disease by ...
Restasis (cyclosporine) is a brand-name drug that’s prescribed for chronic dry eye in adults and certain children. Restasis comes as an eye drop solution. The typical dosage is one drop per ...
Bausch + Lomb is acquiring Johnson & Johnson’s Blink line of eye drops. The deal comes as J ... Dry eye disease drug Xiidra is the centerpiece of the Bausch + Lomb acquisition.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback